CVR number 31365023
Industry 75.0000 Veterinary activities

BLAABJERGS DYREKLINIK ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  3.3% 4.1% 4.0% 3.2% 3.2%  
Credit score (0-100)  54 47 49 55 55  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  999 919 933 1,258 1,464  
EBITDA  360 230 249 529 673  
EBIT  292 164 193 467 616  
Pre-tax profit (PTP)  287.5 156.0 187.7 468.4 618.4  
Net earnings  224.1 120.9 146.7 372.5 482.1  
Pre-tax profit without non-rec. items  287 156 188 468 618  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  1,020 955 902 878 821  
Shareholders equity total  1,586 1,593 1,626 1,880 2,241  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,017 1,805 1,886 2,255 2,562  
Net Debt  -675 -622 -725 -1,102 -1,465  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  999 919 933 1,258 1,464  
Gross profit growth  14.6% -8.1% 1.5% 34.8% 16.4%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,017 1,805 1,886 2,255 2,562  
Balance sheet change%  18.0% -10.5% 4.5% 19.5% 13.6%  
Added value  360.0 229.6 249.1 523.6 672.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -136 -130 -109 -86 -114  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  29.2% 17.9% 20.7% 37.1% 42.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  15.7% 8.6% 10.5% 22.6% 25.7%  
ROI %  19.0% 10.3% 12.0% 26.7% 30.1%  
ROE %  14.7% 7.6% 9.1% 21.2% 23.4%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  78.6% 88.3% 86.2% 83.4% 87.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -187.5% -270.7% -290.9% -208.2% -217.8%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  2.0 3.3 3.1 3.2 4.8  
Current Ratio  2.3 4.1 3.8 3.7 5.4  
Cash and cash equivalent  674.9 621.8 724.6 1,102.3 1,464.8  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  570.4 643.6 727.9 1,002.5 1,419.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  360 230 249 524 673  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  360 230 249 529 673  
EBIT / employee  292 164 193 467 616  
Net earnings / employee  224 121 147 372 482